Kineticos takes an immersive stance with their biotech engagements and investments, working closely in a collaborative effort with key leadership roles in the companies they support. By advising emerging organizations on all phases of the life cycle and helping them succeed through commercialization and beyond, Kineticos and their clients benefit from a return on their investments through equity growth while contributing to improved patient outcomes. With their ultimate goal to play an impactful role in developing cures for cancer and rare diseases, the company leverages its highly experienced and knowledgeable staff to partner with those organizations most likely to positively impact patient health. Philip Gialenios, President and Chief Operating Officer of Kineticos Life Sciences, met with Pharma’s Almanac Editor in Chief David Alvaro to explain how the company is helping to advance novel therapies by having its consulting advisors work directly with companies and offering potential support through its investment activities to identify, establish, and execute effective growth strategies.

About Kineticos:

Kineticos is an award-winning firm with a dual focus on providing advisory services and capital to emerging life sciences firms.  Our mission is simple: to improve patient outcomes. Every day, we see how biotechs are changing the standards of care in medicine. With over 6,000 firms globally, biotechs are the catalysts of innovation in life sciences today; yet emerging companies often have limited resources to focus on strategy and capital, and addressing these challenges is at the core of our capabilities. Join us in our mission to improve patient outcomes by advancing the boundaries of scientific research, development, and commercialization.

Media Contact

Nathan Finger, Senior Director of Commercial Operations